Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact

Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact

ABSTRACT Tislelizumab, an anti‐programmed cell death protein‐1 monoclonal antibody, has demonstrated improved survival over the standard of care for multiple cancers. However, tislelizumab's effectiveness across different racial/ethnicity groups warrants further evaluation. This clinical pharma...

Full description

Saved in:
Bibliographic Details
Main Authors: Tian Yu, Chi‐Yuan Wu, Srikumar Sahasranaman, Xianbin Tian, Ying Fei Li, Zhiyu Tang, Yanfei Yang, Ya Wan, Quting Zhang, Patrick Schnell, Ariadna Mendoza‐Naranjo, Ramil Abdrashitov, William D. Hanley, Nageshwar Budha
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Clinical and Translational Science
Subjects:
exposure–response
immunogenicity
pharmacokinetics
race impact
tislelizumab
Online Access:https://doi.org/10.1111/cts.70221
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70221

Similar Items